Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$569000.0.

  • Editas Medicine's Non Operating Income fell 11614.18% to -$569000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 10865.74%. This contributed to the annual value of $14.1 million for FY2024, which is 1192.21% down from last year.
  • Latest data reveals that Editas Medicine reported Non Operating Income of -$569000.0 as of Q3 2025, which was down 11614.18% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Non Operating Income ranged from a high of $5.1 million in Q3 2023 and a low of -$1.8 million during Q2 2025
  • Over the past 5 years, Editas Medicine's median Non Operating Income value was $1.2 million (recorded in 2024), while the average stood at $1.8 million.
  • Per our database at Business Quant, Editas Medicine's Non Operating Income soared by 145632.18% in 2022 and then tumbled by 14092.18% in 2025.
  • Over the past 5 years, Editas Medicine's Non Operating Income (Quarter) stood at $174000.0 in 2021, then skyrocketed by 1456.32% to $2.7 million in 2022, then surged by 87.89% to $5.1 million in 2023, then crashed by 76.45% to $1.2 million in 2024, then plummeted by 147.5% to -$569000.0 in 2025.
  • Its Non Operating Income stands at -$569000.0 for Q3 2025, versus -$1.8 million for Q2 2025 and -$425000.0 for Q1 2025.